These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8434805)

  • 41. Successful treatment of Raynaud's Syndrome with prostacyclin.
    Belch JJ; Newman P; Drury JK; Capell H; Leiberman P; James WB; Forbes CD; Prentice CR
    Thromb Haemost; 1981 Jun; 45(3):255-6. PubMed ID: 7025341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 43. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The use of capillary videomicroscopy in the therapeutic assessment of acral vasospastic phenomena: microcirculatory effect of ketanserin and nifedipine].
    Gasser P
    Schweiz Rundsch Med Prax; 1994 Apr; 83(17):511-4. PubMed ID: 8191194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome.
    Kahan A; Weber S; Amor B; Menkes CJ
    Lancet; 1983 Mar; 1(8323):538. PubMed ID: 6131248
    [No Abstract]   [Full Text] [Related]  

  • 48. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
    Belch JJ; Newman P; Drury JK; McKenzie F; Capell H; Leiberman P; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):313-5. PubMed ID: 6130329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ketanserin in the treatment of progressive systemic sclerosis.
    Altomare GF; Pigatto PD; Polenghi MM
    Angiology; 1988 Jul; 39(7 Pt 1):583-6. PubMed ID: 3408023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Medical and surgical treatment of Raynaud's phenomenon].
    Van de Wal HJ
    Phlebologie; 1987; 40(1):51-4. PubMed ID: 3554279
    [No Abstract]   [Full Text] [Related]  

  • 51. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study.
    Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ
    Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Digital necrosis in Raynaud's phenomenon revealing a testicular seminoma. Value of prostacyclin].
    Taillan B; Ferrari E; Castanet J; Campagni JP; Garnier G; Fuzibet JG; Benchimol D; Dujardin P
    Presse Med; 1992 Jun; 21(23):1070-1. PubMed ID: 1387938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serotonin and Raynaud's phenomenon.
    Seibold JR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S95-8. PubMed ID: 2412070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)].
    Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T
    Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The importance of presynaptic beta receptors in Raynaud's disease.
    Brotzu G; Falchi S; Mannu B; Montisci R; Petruzzo P; Staico R
    J Vasc Surg; 1989 Jun; 9(6):767-71. PubMed ID: 2542629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Raynaud's phenomenon: effects of terazosin].
    Paterna S; Pinto A; Arrostuto A; Cannavò MG; Di Pasquale P; Cottone C; Licata G
    Minerva Cardioangiol; 1997 May; 45(5):215-21. PubMed ID: 9273472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis.
    Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G
    Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcutaneous electrical nerve stimulation (TENS) in Raynaud's phenomenon.
    Mulder P; Dompeling EC; van Slochteren-van der Boor JC; Kuipers WD; Smit AJ
    Angiology; 1991 May; 42(5):414-7. PubMed ID: 2035894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The treatment of Raynaud's phenomenon.
    Seibold JR; Allegar NE
    Clin Dermatol; 1994; 12(2):317-21. PubMed ID: 8076271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.